<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033094</url>
  </required_header>
  <id_info>
    <org_study_id>MORPH-A-U403</org_study_id>
    <nct_id>NCT04033094</nct_id>
  </id_info>
  <brief_title>Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)</brief_title>
  <acronym>BEAD-MB</acronym>
  <official_title>Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond ER (BEAD-MB) (PMR 2961-9)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to provide surveillance/descriptive data to (a) assess
      utilization of MorphaBond ER and selected comparators overall and by age group and census
      regions using nationally-projected quarterly drug dispensing data and (b) assess the scope
      and pattern of abuse and clinical outcomes for MorphaBond ER using nationally representative
      data or data from large geographic areas in different populations.

      Findings of this study will support the design of formal epidemiology assessment of the risks
      of addiction, overdose, and death outcomes associated with MorphaBond ER and appropriate
      comparators in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study started after the launch of MorphaBond ER in October 2017 and will continue until
      September 2020 and the final study report will be submitted to the FDA by December 2020.

      This is an observational study that will provide descriptive data on the utilization and
      abuse of MorphaBond ER and related outcomes (addiction, misuse, abuse, overdose,
      overdose-related deaths) for MorphaBond ER and selected comparators in response to the
      US-FDA's post-marketing requirement (PMR 2961-9 for MorphaBond ER).

      No investigational products or pharmaceutical agents will be provided or administered for the
      purpose of this study. Multiple data sources, representing different populations and large
      geographic areas in the US, will be utilized to study the patterns of MorphaBond ER
      utilization and abuse and related outcomes.

      The overall purpose of this study is to collect meaningful baseline data to support
      subsequent studies for formal epidemiologic assessment of abuse deterrence of MorphaBond ER
      as required by the FDA.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quarterly number of MorphaBond Extended Release (ER) dosage unit dispensed</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage and rates of abuse/abuse-related outcomes of MorphaBond Extended Release (ER) vs. comparators</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of misuse of MorphaBond Extended Release (ER) vs. comparators</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of addiction of MorphaBond Extended Release (ER) vs. comparators</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overdose rates of MorphaBond Extended Release (ER) vs. comparators</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall mortality rates and opioid overdose death rates of MorphaBond Extended Release (ER) vs. comparators</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of abuse-related outcomes by routes of administration (e.g. ingestion, inhalation, etc).</measure>
    <time_frame>October 2017 through September 2020</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Baseline Epidemiologic Assessment</condition>
  <arm_group>
    <arm_group_label>MorphaBond ER</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This was a retrospective, non-interventional study.</intervention_name>
    <description>Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).</description>
    <arm_group_label>Comparator Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This was a retrospective, non-interventional study.</intervention_name>
    <description>Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.</description>
    <arm_group_label>MorphaBond ER</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MorphaBond ER users and relevant comparator users
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  MorphaBond ER users or relevant comparator users

        Exclusion Criteria:

          -  Not applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safety Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daiichi Sankyo, Inc.</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abuse</keyword>
  <keyword>Misuse</keyword>
  <keyword>Overdose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

